Product Composition

Each uncoated modified release tablet contains:

• Doxofylline IP: 650 mg.

• Excipients: q.s. (sufficient quantity).

Product Summary

Dfilin-650 is a respiratory medication marketed by Healthgate. It contains Doxofylline in a modified-release (MR) formulation, which is a bronchodilator used to treat chronic obstructive pulmonary disease (COPD), asthma, and chronic bronchitis. By relaxing the smooth muscles of the bronchial airways, it helps to improve airflow and ease breathing difficulties over an extended period.

Pros and Cons

Pros

• Extended Duration: The modified-release (MR) formulation allows for a more consistent level of medication in the bloodstream, reducing the frequency of dosing.

• Enhanced Safety Profile: Doxofylline is generally associated with fewer cardiovascular and central nervous system side effects compared to traditional xanthine derivatives.

• High Potency: The 650 mg strength is effective for patients requiring higher maintenance doses for chronic airway management.

Cons

• Delayed Onset: Because it is designed for modified release, it is not suitable for the rapid relief of sudden, acute breathing attacks.

• Potential Side Effects: May cause common reactions such as nausea, headache, or occasional palpitations.

• Drug Interactions: Requires careful medical supervision if taken alongside other medications, such as certain antibiotics or heart medicines.

How to Use

• Administration: Swallow the tablet whole with a glass of water. Do not crush, chew, or break the tablet, as this will destroy the modified-release mechanism.

• Timing: For best results, take the medication consistently at the same time each day as directed by your physician.

• Storage: Store in a cool, dry, and dark place. Protect the medication from exposure to light and moisture.

• Safety: Keep out of reach of children.

Warning: This is a Schedule H Prescription Drug and should be used strictly according to the prescription of a Registered Medical Practitioner.